Title: Further Use of Protein Kinase N Beta. Number: 20040106569. Filed: Aug. 14, 2003. Lead Inventor: Anke Klippel-Giese, Atugen.

According to the patent application's abstract, the invention "is related to the use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI-3 kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.